Interested in becoming a principal researcher? Read this first.
Mark Packer, MD, FACS, CPI
Advertisement
Articles by Mark Packer, MD, FACS, CPI
Rho kinase inhibitors are intriguing in that they work directly on the pathogenic mechanism of abnormally elevated IOP, increased resistance to trabecular outflow.
Advertisement
Latest Updated Articles
- Pearls and pitfalls for principal investigators
March 8th 2018
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
2
Opus Genetics reaches FDA alignment on phase 3 registrational design for OPGx-LCA5 gene therapy
3
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
4
Port Delivery System Therapies in Retinal Vascular Diseases
5